Advertisement
Original paper Cellular immunotherapy| Volume 17, ISSUE 7, P979-988, July 2015

Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma

Published:April 15, 2015DOI:https://doi.org/10.1016/j.jcyt.2015.03.605
Combined cellular immunotherapy and chemotherapy improves clinical outcome in patients with gastric carcinoma
Previous ArticleHuman allogeneic AB0/Rh-identical umbilical cord blood cells in the treatment of juvenile patients with cerebral palsy
Next ArticleSelection of adenovirus-specific and Epstein-Barr virus–specific T cells with major histocompatibility class I streptamers under Good Manufacturing Practice (GMP)–compliant conditions

      Abstract

      Background aims

      Despite the availability of multiple treatment strategies, patients with gastric carcinoma (GC) have a dismal prognosis. The aim of this study was to evaluate the efficacy and safety of cellular immunotherapy (CIT) with the use of autologous natural killer cells, γδT cells and cytokine-induced killer cells in combination with chemotherapy in patients with GC.

      Methods

      In this open-label pilot cohort study, patients were treated with the combination therapy (chemo/CIT group) or chemotherapy alone (control group). Progression-free survival (PFS), overall survival (OS), quality of life (QOL) and adverse events were investigated.

      Results

      Fifty-eight patients were analyzed, 30 in the chemo/CIT group and 28 in the control group. The median PFS of the chemo/CIT group was significantly longer compared with the control group (P = 0.021). In subgroup analysis, in patients with stage III GC, node-positive metastasis or poorly differentiated carcinoma, the 2-year PFS rate in chemo/CIT versus control groups was 62.5% versus 26.7% (P = 0.022), 50% versus 27.3% (P = 0.016) and 56.3% versus 28.6% (P = 0.005), respectively. The median OS in either group has not yet been reached, and there was no significant difference in OS between the groups. The QOL was improved in the patients treated with chemo/CIT compared with the control group. CIT was well tolerated and not related to any significant adverse events.

      Conclusions

      A combination of CIT and chemotherapy for patients with GC was safe, improved QOL, and might prevent recurrence, especially in GC patients with advanced stage, poorly differentiated carcinoma or lymph node metastasis.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      References

        • Jemal A.
        • Bray F.
        • Center M.M.
        • Ferlay J.
        • Ward E.
        • Forman D.
        Global cancer statistics.
        CA Cancer J Clin. 2011; 61: 69-90
        View in Article
        • Macdonald J.S.
        • Smalley S.R.
        • Benedetti J.
        • Hundahl S.A.
        • Estes N.C.
        • Stemmermann G.N.
        • et al.
        Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.
        N Engl J Med. 2001; 345: 725-730
        View in Article
        • Kiessling R.
        • Wasserman K.
        • Horiguchi S.
        • Kono K.
        • Sjöberg J.
        • Pisa P.
        • et al.
        Tumor-induced immune dysfunction.
        Cancer Immunol Immunother. 1999; 48: 353-362
        View in Article
        • Xie Z.J.
        • Liu Y.
        • Jia L.M.
        • He Y.C.
        Heparanase expression, degradation of basement membrane and low degree of infiltration by immunocytes correlate with invasion and progression of human gastric cancer.
        World J Gastroenterol. 2008; 14: 3812-3818
        View in Article
        • Dudley M.E.
        • Rosenberg S.A.
        Adoptive-cell-transfer therapy for the treatment of patients with cancer.
        Nat Rev Cancer. 2003; 3: 666-675
        View in Article
        • Gilboa E.
        How tumors escape immune destruction and what we can do about it.
        Cancer Immunol Immunother. 1999; 48: 382-385
        View in Article
        • Fisch P.
        • Moris A.
        • Rammensee H.G.
        • Handgretinger R.
        Inhibitory MHC class I receptors on gammadelta T cells in tumour immunity and autoimmunity.
        Immunol Today. 2000; 21: 187-191
        View in Article
        • Mimura K.
        • Kamiya T.
        • Shiraishi K.
        • Kua L.
        • Shabbir A.
        • So J.
        • et al.
        Therapeutic potential of highly cytotoxic natural killer cells for gastric cancer.
        Int J Cancer. 2014; 135: 1390-1398
        View in Article
        • Maniar A.
        • Zhang X.
        • Lin W.
        • Gastman B.R.
        • Pauza C.D.
        • Strome S.E.
        • et al.
        Human gam-madelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement.
        Blood. 2010; 116: 1726-1733
        View in Article
        • Jiang J.
        • Wu C.
        • Lu B.
        Cytokine-induced killer cells promote antitumor Immunity.
        J Transl Med. 2013; 11: 83
        View in Article
        • Lu P.H.
        • Negrin R.S.
        A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.
        J Immunol. 1994; 153: 1687-1696
        View in Article
        • Morisaki T.
        • Onishi H.
        • Katano M.
        Cancer immunotherapy using NKG2D and DNAM-1 systems.
        Anticancer Res. 2012; 32: 2241-2247
        View in Article
        • Peng Y.P.
        • Zhu Y.
        • Zhang J.J.
        • Xu Z.K.
        • Qian Z.Y.
        • Dai C.C.
        • et al.
        Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer.
        J Transl Med. 2013; 11: 262
        View in Article
        • Lake R.A.
        • Robinson B.W.
        Immunotherapy and chemotherapy–a practical partnership.
        Nat Rev Cancer. 2005; 5: 397-405
        View in Article
        • Gasser S.
        • Orsulic S.
        The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor.
        Nature. 2005; 436: 1186-1190
        View in Article
        • Kershaw M.H.
        • Devaud C.
        • John L.B.
        • westwood J.A.
        • Darcy P.K.
        Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.
        OncoImmunology. 2013; (1–6): e25962
        View in Article
        • Eisenhauer E.A.
        • Therasse P.
        • Bogaerts J.
        • Schwartz L.H.
        • Sargent D.
        • Ford R.
        • et al.
        New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
        Eur J Cancer. 2009; 45: 228-247
        View in Article
        • Aaronson N.K.
        • Ahmedzai S.
        • Bergman B.
        • Bullinger M.
        • Cull A.
        • Duez N.J.
        • et al.
        The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
        J Natl Cancer Inst. 1993; 85: 365-376
        View in Article
        • Vickey C.W.
        • Blazeby J.M.
        • Conroy T.
        • Arraras J.
        • Sezer O.
        • Koller M.
        • et al.
        Development of an EORTC disease-special quality of life modules for use in patients with gastric cancer.
        Eur J Cancer. 2001; 37: 966-971
        View in Article
        • Cui J.
        • Wang N.
        • Zhao H.
        • Jin H.
        • Wang G.
        • Niu C.
        • et al.
        Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
        Int J Cancer. 2014; 134: 342-351
        View in Article
        • Dewan M.Z.
        • Terunuma H.
        • Takada M.
        • Tanaka Y.
        • Abe H.
        • Sat T.
        Role of natural killer cells in hormone-independent rapid tumor formation and spontaneous metastasis of breast cancer cells in vivo.
        Breast Cancer Res Treat. 2007; 104: 267-275
        View in Article
        • Kondo M.
        • Sakuta K.
        • Noguchi A.
        • Ariyoshi N.
        • Sato K.
        • Sato S.
        • et al.
        Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy.
        Cytotherapy. 2008; 10: 842-856
        View in Article
        • Wick M.
        • Dubey P.
        • Koeppen H.
        • Siegel C.T.
        • Fields P.E.
        • Chen L.
        • et al.
        Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy.
        J Exp Med. 1997; 186: 229
        View in Article
        • Pawelec G.
        • Zeuthen J.
        • Kiessling R.
        Escape from host-antitumor immunity.
        Crit Rev Oncog. 1997; 8: 111
        View in Article
        • Saito H.
        • Osaki T.
        • Ikeguchi M.
        Decreased NKG2D expression on NK cells correlates with impaired NK cell function in patients with gastric cancer.
        Gastric Cancer. 2012; 15: 27-33
        View in Article
        • Végh Z.
        • Wang P.
        • Vánky F.
        • Klein E.
        Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumors.
        Cancer Res. 1993; 53: 2416-2420
        View in Article
        • Shi L.
        • Zhou Q.
        • Wu J.
        • Ji M.
        • Li G.
        • Jiang J.T.
        • et al.
        Efficacy of adjuvant immunotherapy with cytokine-induced killer cells in patients with locally advanced gastric cancer.
        Cancer Immunol Immunother. 2012; 6: 2251-2259
        View in Article
        • McKernan M.
        • McMillan D.C.
        • Anderson J.R.
        The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer.
        Br J Cancer. 2008; 98: 888-893
        View in Article
        • Barsevick A.
        • Frost M.
        • Zwinderman A.
        • Hall P.
        • Halyard M.
        I'm so tired: biological and genetic mechanisms of cancer-related fatigue.
        Qual Life Res. 2012; 19: 1419-1427
        View in Article
        • Christopher G.
        • Digant G.
        • Carolyn A.L.
        • Maurie M.
        • Pankaj G.V.
        Role of nutritional status in predicting quality of life outcomes in cancer a systematic review of the epidemiological literature.
        Nutrition Journal. 2012; 11: 27
        View in Article

      Article info

      Publication history

      Published online: April 15, 2015
      Accepted: March 4, 2015
      Received: January 21, 2015

      Identification

      DOI: https://doi.org/10.1016/j.jcyt.2015.03.605

      Copyright

      © 2015 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX